Dow Dips 600 Points; AMC Entertainment Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 600 points on Thursday.
Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 600 points on Thursday.
Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday.
Dow Jumps Over 550 Points; Nike Earnings Beat Views
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 550 points on Wednesday.
AstraZeneca Announced Earlier Lynparza Approved in EU for Prostate Cancer; AstraZeneca to Receive $105M Milestone Payment from Merck
AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men for whom chemotherapy is not clinically indicated.
US Stocks Slightly Lower; Nasdaq Down 100 Points
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 100 points on Monday.
3 Consumer Staples Stocks Paying Solid Dividends May Protect Your Portfolio During Downturn
During times of recession or high inflation, people will still need to purchase everyday necessities such as food, cleaning supplies, and hygiene products.
AstraZeneca Earlier Announced Forxiga Recommended for Approval in the EU by CHMP for Symptomatic Chronic Heart Failure
AstraZeneca's Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) to extend the indication for heart failure with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF) including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).
AstraZeneca Announced Enhertu Recommended for Approval in the EU by CHMP for Patients with HER2-low Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to demonstrate a significant survival benefit vs. chemotherapy in this patient population.
Dow Tumbles 400 Points; Maxar Technologies Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Friday.